The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
Japan’s key drug pricing panel on September 20 held its second round of industry hearings towards the FY2024 reimbursement reform. Groups of research-driven pharma companies in Japan, the US, and Europe formed a united front to put forward a set…
To read the full story
Related Article
- Chuikyo Rep Grumbles at Too Many Industry Requests, FPMAJ Chief Wants Health Coverage Dabate
September 21, 2023
- Apply Brand-Based Price Revisions to Qualified Generic Makers: JGA
September 21, 2023
- JPWA Urges Price Hikes for Drugs with NHI Tag Below 20 Yen
September 21, 2023
REGULATORY
- Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
- Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
- Antivirals, Cancer Drugs Flagged in PMDA Risk Review
January 19, 2026
- Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
- Japan Panel to Review Pfizer’s Cancer Med Tukysa on January 29
January 16, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…